Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-27 @ 11:38 PM
Study NCT ID:
NCT06350734
Status:
RECRUITING
Last Update Posted:
2025-10-20
First Post:
2024-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Sponsor:
Mayo Clinic
Organization:
Study Overview
Official Title:
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Status:
RECRUITING
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the effect of bladder cancer treatment on quality of life.
Detailed Description:
PRIMARY OBJECTIVES:
I. To compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively.
II. To identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer.
OUTLINE: This is an observational study.
Patients complete surveys and also have their medical records reviewed on study.
I. To compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively.
II. To identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer.
OUTLINE: This is an observational study.
Patients complete surveys and also have their medical records reviewed on study.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: